Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results entities : Merck & company, inc. save search
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: 2.37%
H: 1.46%
C: 1.22%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.6%
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: -2.77%
H: 0.47%
C: -0.27%
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 81.31%
H: 29.0%
C: 21.9%
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 2.1%
H: 2.83%
C: -0.5%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: 14.46%
H: 11.02%
C: 4.72%
ALDX | $3.93 0.51% 0.51% 570K
|
Health Technology
|
| O: 1.91%
H: 2.68%
C: 1.07%
year financial results
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -4.37%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 2.38%
H: 2.25%
C: 2.21%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.15%
H: 0.1%
C: -1.86%
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
merck financial results
Merck Announces Third-Quarter 2023 Financial Results
Published: 2023-10-26 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.51%
H: 4.0%
C: 2.38%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.04%
H: 0.64%
C: -0.98%
merck financial results
Merck Announces First-Quarter 2023 Financial Results
Published: 2023-04-27 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.03%
H: 0.66%
C: 0.49%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.13%
H: 1.05%
C: -0.63%
merck financial results
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 7.92%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.8%
H: 0.6%
C: -0.29%
propel symposium trial results
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 1.22%
H: 0.0%
C: -1.61%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -2.77%
H: 1.72%
C: -0.54%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.37%
H: 1.07%
C: 0.66%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.52%
H: 1.92%
C: 1.7%
financial results
Merck Announces Third-Quarter 2022 Financial Results
Published: 2022-10-27 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.45%
H: 1.66%
C: -0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 0.97%
H: 2.0%
C: 0.51%
financial results
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
Published: 2022-10-10 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 2.66%
H: 1.84%
C: 0.61%
treatment hypertension trial positive
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
Published: 2022-09-12 (Crawled : 13:20) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.71%
H: 0.14%
C: -1.05%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.9%
H: 1.17%
C: 0.03%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -3.57%
padcev trial results cancer
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Published: 2022-06-21 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
vaccine positive phase 1 pneumococcal
Organon Reports Results for the First Quarter Ended March 31, 2022
Published: 2022-05-05 (Crawled : 12:20) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.98%
H: 0.27%
C: -0.46%
Merck Announces First-Quarter 2022 Financial Results
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.96%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.36%
H: 0.0%
C: 0.0%
results
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
Published: 2022-04-21 (Crawled : 12:20) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
conference report results
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
Published: 2022-02-17 (Crawled : 13:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.48%
H: 0.1%
C: -0.64%
report results
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
Published: 2022-02-03 (Crawled : 13:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.27%
H: 0.18%
C: -3.23%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
financial results ces results
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
Published: 2022-02-01 (Crawled : 13:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.04%
H: 0.19%
C: -0.05%
conference report results
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
Published: 2022-01-20 (Crawled : 13:30) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.31%
H: 1.4%
C: 0.02%
ynote-775 keytruda trial results phase 3
Organon Reports Results for the Third Quarter Ended September 30, 2021
Published: 2021-11-11 (Crawled : 16:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.11%
H: 0.41%
C: 0.12%
results
Acceleron Reports Third Quarter 2021 Financial Results
Published: 2021-11-04 (Crawled : 21:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 1.8%
H: 1.14%
C: 0.19%
financial results results
Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 2.26%
H: 4.17%
C: 3.8%
results conference
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.